Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE

Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/33868

Title:	Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE
Authors:	GEYER JR., C. E.; HUANG, C-S; MANO, M. S.; LOIBL, S.; MAMOUNAS, E. P.; UNTCH, M.; WOLMARK, N.; RASTOGI, P.; FISCHER, H. H.; REDONDO, A.; JACKISCH, C.; JACOT, W.; CONLIN, A. K.; SCHNEEWEISS, A.; WAPNIR, I. L.; FASCHING, P. A.; DIGIOVANNA, M. P.; WUELFING, P.; ARCE-SALINAS, C.; CROWN, J. P.; SHAO, Z.; CAREMOLI, E. Rota; WU, H.; LAM, L. H.; TESAROWSKI, D.; SMITT, M.; DOUTHWAITE, H.; SINGEL, S. M.; MINCKWITZ, G. von
Citation:	CANCER RESEARCH, v.79, n.4, suppl.S, 2019
Appears in Collections:	Comunicações em Eventos - FM/Outros Outros departamentos - FM/Outros

Files in This Item:

There are no files associated with this item.